PainTEQ Secures Majority Growth Recapitalization Co-Led by Signet Healthcare Partners & Windham Capital Partners :

Strategic equity investment to accelerate growth and innovation in interventional spine care.

PainTEQ, a leader in minimally invasive solutions for sacroiliac (SI) joint dysfunction, today announced a majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners, two U.S.-based healthcare investment firms with nearly 50 years of combined investment experience in medical technology companies. This recapitalization also includes a new equity investment by MVolution Partners.

With new ownership, this strategic investment will accelerate PainTEQ’s expansion by funding prospective clinical studies, advancing development of next-generation products, and expanding the company’s U.S. commercial presence.

PainTEQ’s flagship product, LinQ^®, is a proprietary, allograft-based, drill-less SI joint implant delivered via a minimally invasive posterior approach. To date, LinQ^® has been used in over 14,000 procedures and is supported by multiple peer-reviewed clinical studies, including the SECURE study, a prospective clinical trial demonstrating improvements in pain and function alongside a strong safety profile.

Under the leadership of CEO Shanth Thiyagalingam, PainTEQ has demonstrated strong operational discipline and commercial leadership. Thiyagalingam brings more than two decades of interventional experience, including senior commercial leadership roles at Abbott, Nevro, and Stryker.

“Partnering with experienced institutional healthcare investors at Signet and Windham marks an exciting chapter for PainTEQ,” said Thiyagalingam. “With a strengthened balance sheet and new committed ownership group, we are well positioned to deliver innovative solutions for patients suffering from SI joint dysfunction and to continue building a category-leading interventional platform. We are grateful to the founding team and prior owners for laying the groundwork that enables this next phase of company growth.”

Dr. Dawood Sayed, Professor and Division Chief of Pain Medicine at the University of Kansas Medical Center and Vice Chair and Co-Founder of the American Society of Pain and Neuroscience (ASPN), commented: “This investment validates SI joint fusion as a critical treatment pathway. It will accelerate innovation and advance research, expanding treatment options in interventional spine care and making this procedure a long-term standard of care.”

David Kereiakes, Managing Partner at Windham Capital Partners, commented: “We were compelled to invest in a future that delivers safer, more effective solutions for physicians and patients. PainTEQ’s innovative, minimally invasive technology and strong leadership are exactly what the interventional spine care market needs.”

Ashley Friedman, Managing Director at Signet Healthcare Partners, also added: “We are delighted to partner with Shanth and the PainTEQ team to leverage the company’s leadership position in SI joint treatment. With additional investment in clinical studies and pipeline products, we believe PainTEQ is well positioned to become a leading multi-product interventional spine platform.”

Raymond James served as financial advisor to PainTEQ. Legal counsel included Hill Ward Henderson; Bass, Berry & Sims; Sheppard, Mullin, Richter & Hampton; and Knobbe Martens. Transaction terms were not disclosed.

 

About PainTEQ: PainTEQ was built to bring interventional procedures to the market. Working with pain management specialists to help reduce and eliminate SI joint dysfunction, PainTEQ’s  LinQ implant and single-use instruments aim to immediately provide clinical benefits to individuals living with incapacitating lower back pain through a minimally invasive outpatient procedure. Learn more at www.painteq.com. 

About LinQ: The LinQ SI Joint Stabilization System provides patients with a minimally invasive option to combat pain due to sacroiliac disease. After a thorough diagnostic process, physicians may help alleviate – and in many cases eliminate – chronic pain by placing a single LinQ allograft into the SI joint. With its large graft window, the LinQ implant is designed to create an ideal environment for long-term fusion.